Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03629340 · ClinicalTrials.gov registry record · Phase 2
Metformin for Pulmonary Hypertension HFpEF
A Phase 2 study of Heart Failure and Pulmonary Hypertension, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT03629340 is a Phase 2 study of Heart Failure and Pulmonary Hypertension that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03629340, a Phase 2 study of Heart Failure and Pulmonary Hypertension, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Placebo oral capsule
Study Locations (2)
California
- UCSF Medical Center - San Francisco
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03629340
The ClinicalTrials.gov registry entry for NCT03629340 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT03629340 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03629340 about?
NCT03629340 is a clinical study titled "Metformin for Pulmonary Hypertension HFpEF". The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
What is the current status of trial NCT03629340?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-02-26. Estimated completion is 2026-02.
What conditions does trial NCT03629340 study?
This clinical trial studies the following conditions: Heart Failure, Pulmonary Hypertension.
What interventions are being tested in trial NCT03629340?
The interventions under investigation include: Metformin (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03629340?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03629340 being conducted?
This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
-
Ertugliflozin in Chronic Heart Failure
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.